Alterations in Circulating MicroRNAs and the Relation of MicroRNAs to Maximal Oxygen Consumption and Intima–Media Thickness in Ultra-Marathon Runners

Ceren Eyileten 1, Alex Fitas 1, Daniel Jakubik 1, Pamela Czajka 1, Anna Mróz 2, Anna Czajkowska 3, Katarzyna Witek 3, Wawrzyniec Bakalarski 3, Salvatore De Rosa 4, Marek Postula 1,* and Łukasz A. Malek 5

1 Center for Preclinical Research and Technology CEPT, Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 02-097 Warsaw, Poland; ceyileten@wum.edu.pl (C.E.); fitas.alex2@gmail.com (A.F.); djakubik@wum.edu.pl (D.J.); czajka.pamela@gmail.com (P.C.)
2 Department of Physical Education, Józef Piłsudski University of Physical Education in Warsaw, 00-809 Warsaw, Poland; anna.mroz@awf.edu.pl
3 Department of Tourism and Recreation, Józef Piłsudski University of Physical Education in Warsaw, 00-809 Warsaw, Poland; anna.czajkowska@awf.edu.pl (A.C.); katarzyna.witek@awf.edu.pl (K.W.); wawrzyniec.bakalarski@awf.edu.pl (W.B.)
4 Division of Cardiology, Department of Medical and Surgical Sciences, “Magna Graecia” University, 88100 Catanzaro, Italy; saderosa@unicz.it
5 Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, Institute of Cardiology, 04-628 Warsaw, Poland; lmalek@ikard.pl
* Correspondence: mpostula@wum.edu.pl; Tel.: +48-22-116-6160

Abstract: The impact of long-term training on cardiovascular disease (CVD) is not clear. Carotid intima–media thickness (CIMT) test is recommended as a useful measure to diagnose the early stages of atherosclerosis. MicroRNAs (miRNAs) are altered due to endurance exercise and can be promising biomarkers of pathophysiological changes. We aimed to evaluate the association of circulating miRNAs with physical fitness and markers of atherosclerosis in ultra-marathon runners. Ultra-marathon runners had 28-fold upregulation of miR-125a-5p expressions compared to control individuals \((p = 0.002)\), whereas let-7e and miR-126 did not differ statistically between ultra-marathon runners and controls. In the ultra-marathon runners’ group, negative correlations were observed between \(V_{O2\max}/kg\) and relative expression of miR-125a-5p and miR-126 \((r = -0.402, p = 0.028; r = -0.438, p = 0.032, respectively)\). Positive correlations were observed between CIMT and miR-125a-5p and miR-126 \((r = 0.388, p = 0.050; r = 0.504, p = 0.023, respectively)\) in ultra-marathon runners. Individuals with the highest quartile of \(V_{O2\max}/kg\) had 23-fold lower miR-126 expression in comparison to subgroups with lower \(V_{O2\max}/kg\) \((p = 0.017)\). Our results may indicate that both miRNAs may serve as a biomarker for early pathological changes leading to atherosclerosis burden in athletes. Furthermore, the association between miRNAs and traditional risk factors for CVD indicate a possible use of these molecules as early biomarkers of future cardiovascular health.

Keywords: microRNA; miRNA; endurance sport; cardiovascular disease; atherosclerosis

1. Introduction

Long-term endurance training can be defined as workouts performed 10–12 times a week and lasting for 15–30 h in case of elite athletes, or 4–5 times for 6–10 h in case of recreational athletes for a longer period of time. Additionally, in both groups, 80% of exercise is performed with the intensity below the lactate threshold, which means with 45–80% of maximal oxygen consumption \((V_{O2\max})\) for more than 60 min, and 20% of high intensity-interval training (HIIT) (lasting 15–90 min per session) [1,2]. This type of training can induce several physiological adaptations in cardiovascular systems, such as balanced enlargement of heart chambers and mild myocardial hypertrophy [3]. Long-term...
endurance training is also related to enhanced VO\textsubscript{2}max [4–6], which leads to increased cardiac output and therefore improves physical fitness [7] and has a protective effect against cardiovascular disease (CVD) [8]. On the other hand, several recent studies suggested that ultra-endurance training can function as a double-edged sword. For example, HIIT is related to muscle hypoxia which may cause oxidative stress, reactive oxygen forms production and enhance inflammation [2,9]. Additionally, high-volume, high-intensity exercise training may induce atherosclerosis due to increased atherosclerotic lesions, however, the exact mechanism is still unknown [10–13]. The early diagnosis of atherosclerosis before the onset of clinical signs and symptoms is difficult. Carotid intima–media thickness (CIMT) test results were found related to cardiovascular risk, thus CIMT was recommended as a potentially useful diagnostic tool in early stages of atherosclerosis [14–18].

MicroRNAs (miRNAs) are a class of small non-coding RNAs that function as regulators of post-transcriptional gene expressions. They can influence cell development, proliferation, differentiation and apoptosis. Moreover, miRNAs may have a relevant regulatory potential in atherosclerosis and pathophysiology of CVDs, through regulating cardiomyocyte hypertrophy, fibrosis and injury [11,19–21]. Importantly, circulating miRNAs are found altered due to endurance exercise. For example, a previous study found circulating miR-126 increased after different forms of endurance exercise in healthy subjects [22]. Moreover, Nielsen et al. showed that acute exercise induced decreases in circulating miR-221 and miR-146a [23], whereas Baggish et al. documented those miRNAs as increased following acute exhaustive exercise [24]. MiRNAs can be promising biomarkers of the cardiovascular physiological adaptations and possible pathophysiological changes due to their high stability in blood plasma and serum [11,23,25–28]. However further analysis of miRNAs’ utility as biomarkers is required as several contradictory results were presented.

MiR-126 deserves special attention as studies show that it can have favorable effects on vascular integrity, angiogenesis, and stabilization of atherosclerotic plaques [22,29,30]. Increased expression of miR-126 endorses a more stabilized plaque phenotype and therefore correlates with a significantly lower frequency of cardiovascular events in patients with coronary artery disease [30,31]. Similarly, some previous studies indicated that miR-125a-5p expressions were decreased in atherosclerotic plaques of coronary atherosclerosis patients [32,33]. However, the underlying molecular mechanism of both miR-126 and miR-125a-5p in the progression of atherosclerosis is still poorly understood. Furthermore, endurance training is associated with increased markers of inflammation following a bout of exercise, and it was suggested that acute endurance exercise causes induction of circulating inflammatory miRNA expression, such as Let-7 family miRNAs [34,35].

Briefly, ultra-endurance exercise is characterized by cardiovascular adaptation. Importantly, several clinical studies on ultra-marathon runners reported that intensive training can be also related to cardiovascular pathological changes [36–39]. However, results are contradictory [40]. Several molecular based studies showed that endurance training may increase oxidative stress, hypoxia and cardiac fibrosis [41,42]. On the other hand, the research of circulating miRNAs involved in response to chronic endurance training is still very limited and study on the influence of extreme high intensity training is missing. Knowledge of the circulating miRNAs levels can advance exercise assessment and may facilitate differential diagnosis concerning adaptive and pathological changes [43]. Consequently, this study aimed to evaluate the miRNAs expression difference between ultra-marathon runners and non-athletic healthy subjects, as well as the association of miR-126, Let-7e and miR-125a-5p with physical fitness (measured with maximal oxygen consumption) and markers of atherosclerosis (CIMT) in ultra-marathon runners.

2. Materials and Methods

2.1. Study Group

The Ethics Committee of the Regional Medical Chamber in Warsaw approved both the study protocol and the informed consent form (no 52/17) [44]. The study was conducted
in accordance with the current version of the Declaration of Helsinki at the time when the study was designed, and informed written consent from all participants was obtained. In this study we included 30 healthy, male, ultra-marathon runners and age-matched non-athletic healthy individuals (N = 9). The full characterization of the study population was published previously [5,6]. Briefly, in the present analysis we included runners with numerous years of documented training, running at least 70 km a week and often participating in ultra-marathon competitions. The detailed medical history of enrolled participants was taken, together with their body mass index (BMI), baseline electrocardiography (ECG), blood pressure (BP) measurement at rest, carotid ultrasound and whole blood count as well as creatinine concentration measurement on the day, but before cardiovascular magnetic resonance imaging. Subsequently all participants underwent cardiovascular magnetic resonance (CMR) with parametric imaging (with pre-contrast T1—time after magnetization inversion and T2—time constant for loss of transverse magnetization-mapping, Siemens Magnetom Skyra 3 T scanner) and gadolinium contrast administration followed by late gadolinium enhancement (LGE) and post-contrast T1-mapping (Siemens, Erlangen, Germany). A cardiopulmonary exercise test (CPET), by using (Saturn, h/p/cosmos, Nussdorf—Traunstein, Germany and Metamax 3B, Cortex Biophysik GmbH, Leipzig, Germany) was performed within 4 weeks of the CMR according to the protocols as described previously [5,6].

2.2. Blood Collection

Approximately 9 mL of blood was obtained from antecubital vein using a plasma separator tube between 12 and 24 h after the last training. Participants were informed to withhold from intensive exercise for 24 h before the blood sampling. Withdrawn blood was kept at room temperature for 30 min. Blood collection tubes were centrifuged at 1500 × g for 15 min at 18–25 ºC. Plasma was aliquoted into 500 µL volumes and stored in −80 ºC freezer until the laboratory analysis.

2.3. RNA Preparation, Detection, and Quantification of miRNAs by Quantitative PCR

In order to purify samples from cell debris, plasma samples after thawing at room temperature were subjected to centrifugation at 16,000 × g for 10 min at 4 ºC. Total RNA was isolated using miRVana PARIS Kit (invitrogen, Applied technologies, Carlsbad, CA, USA) from 500 µL of plasma and diluted at a ratio of 1:10. Subsequently, the obtained RNA template was subjected to a reverse transcription reaction using the TaqMan miRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA) according to guidelines provided by the manufacturer. Afterwards, 3 µL of the product was used to detect miRNA expression by quantitative polymerase chain reaction (qPCR) using TaqMan miRNA Assay kits (ABI, Vernon, CA, USA) for the corresponding miRNAs on a The CFX384 Touch Real-Time PCR Detection System (BioRad Inc., Hercules, CA, USA). Cel-miR-39 was added as an exogenous spike-in control. Mean values of all reactions performed in triplicate were used in statistical analysis [45,46].

2.4. Statistical Analysis

All results for categorical variables were presented as a number and a percentage. Continuous variables were expressed as mean and standard deviation (SD) or median and interquartile range (IQR), depending on the normality of distribution assessed with the use of the Shapiro–Wilk test. Student’s t-test or the Mann-Whitney test for unpaired samples were applied to compare cases and controls depending on the normality of the distribution. To assess the correlation between continuous variables, a Spearman test was applied. Receiver operating characteristic (ROC) curves were used to analyze the relation between miRNAs expressions and maximal intima-media thickness. All tests were two-sided with the significance level of p < 0.05. Calculations were performed using SPSS version 22.0 (IBM Corporation, Chicago, IL, USA).
3. Results

3.1. Participants

Thirty male ultra-marathon runners and nine healthy, non-athletic male subjects were enrolled in this study. The whole cohort completed all required tests. We did not observe any significant differences at the baseline demographics regarding age, anthropometric measures and blood pressure between the studied and control group. Detailed demographic data are presented in Tables 1 and 2 (also previously provided [5,6]).

Table 1. Characteristics of ultra-marathon runners.

| Parameter                       | Ultra-Marathon Runners (n = 30, Median (IQR)) |
|---------------------------------|---------------------------------------------|
| Years of running (running history) | 9 (7–15)                                   |
| Years of ultra-training         | 6 (5–8)                                     |
| Age at start of ultra-running   | 34 (29–39)                                  |
| Total covered distance (km)     | 25,000 (20,000–40,000)                     |
| Weekly running distance (km)    | 80 (70–90)                                  |
| Number of ultra-races completed | 15 (10–27.5)                                |
| Number of ultra-races during previous year | 5.5 (4–9)                              |
| Number of completed ultra-races >100 km | 3.5 (2–7)                               |
| Best place achieved in an ultra-race | 5 (1–13)                                |
| Longest run (km)                | 150 (106–246)                               |
| Most frequent ultra-race distance (km) | 100 (70–100)                          |

Data are reported as median and interquartile range. Abbreviations: standard deviation, SD; interquartile range.

Table 2. Participants baseline characteristics and results.

| Parameter                  | Ultra-Marathon Runners (n = 30) | Control Group (n = 9) | p Value |
|----------------------------|---------------------------------|-----------------------|---------|
| Age (years)                | 40.93 ± 6.57                    | 40.0 ± 8.32           | 0.76    |
| Height (cm)                | 178 ± 5                         | 179 ± 4               | 0.51    |
| Weight (kg)                | 71.9 ± 4.7                      | 83 ± 6.1              | 0.12    |
| BMI (cm/m²)                | 22.07 ± 1.54                    | 26.1 ± 1.5            | 0.13    |
| Systolic BP (mmHg)         | 128 ± 6                         | 126 ± 7               | 0.78    |
| Diastolic BP (mmHg)        | 78 ± 6                          | 80 ± 5                | 0.35    |
| Hct (%/100)                | 0.43 ± 0.03                     | 0.45 ± 0.02           | 0.01 *  |
| Resting HR (bpm)           | 54.9 ± 9.2                      | 69.6 ± 11.0           | 0.005 * |
| VO₂ max (L/min)            | 4.43 ± 0.44                     | 3.63 ± 0.63           | 0.005 * |
| VO₂ max (mL/min/kg)        | 61.0 ± 4.9                      | 40.2 ± 4.6            | <0.001 *|
| VE max (L)                 | 150.4 ± 16.9                    | 127.9 ± 25.3          | 0.03*   |
| RER max                    | 1.08 ± 0.05                     | 1.10 ± 0.04           | 0.17    |
| LVEDVI (mL/m²)             | 110 ± 15                        | 78 ± 10               | <0.0001 *|
| LVESVI (mL/m²)             | 39 ± 9                         | 27 ± 4                | <0.0001 *|
| LVSVI (mL/m²)              | 71 ± 9                         | 51 ± 9                | <0.0001 *|
| LVEF (%)                   | 65 ± 5                         | 66 ± 5                | 0.59    |
| LVMI (g/m²)                | 83 ± 11                         | 66 ± 11               | 0.001 * |
| RVEDVI (mL/m²)             | 125 ± 20                        | 88 ± 12               | <0.0001 *|
| RVESVI (mL/m²)             | 52 ± 11                         | 37 ± 6                | <0.0001 *|
| RVEF (%)                   | 59 ± 4                         | 58 ± 5                | 0.61    |
| RVMI (g/m²)                | 24 ± 3.5                        | 22 ± 5                | 0.24    |
| IVSD (mm)                  | 11.5 ± 2                        | 10.5 ± 1              | 0.32    |
| PWD (mm)                   | 10 ± 1                          | 9 ± 1                 | 0.17    |
| Left CIMT                  | 0.07 ± 0.02                     | 0.07 ± 0.01           | 0.99    |
| Right CIMT                 | 0.08 ± 0.03                     | 0.08 ± 0.01           | 0.68    |

Abbreviations: BMI—body mass index, BP—blood pressure, CIMT—carotid intima–media thickness, Hct—hematocrit, HR—heart rate, IVSD—interventricular septal diameter, LVEDVI—left ventricular end-diastolic volume index, LVEF—left ventricular ejection fraction, LVESVI—left ventricular end-systolic volume index, LVMI—left ventricular mass index, LVSVI—left ventricular stroke volume index, PWD—left ventricular posterior wall diameter, RER—respiratory exchange ratio, RVEF—right ventricular ejection fraction, RVEDVI—right ventricular end-diastolic volume index, RVESVI—right ventricular end-systolic volume index, RVMI—right ventricular mass index, RVSVI—right ventricular stroke volume index, VE—minute ventilation, VO₂ max—maximal oxygen consumption. * p values marked with bold indicate statistically significant differences between the groups.
3.2. Circulating miRNAs

Circulating miRNAs expression was determined in the blood plasma. Ultra-marathon runners had 28-fold upregulation of miR-125a-5p expressions compared to control individuals \((p = 0.002)\), whereas let-7e and miR-126 did not differ statistically between ultra-marathon runners and controls \((p = 0.806; p = 0.140,\) respectively) (Figure 1).

![Figure 1. miRNAs relative expression difference between the groups. (a) miR-125a-5p; (b) Let-7e; (c) miR-126.](image)

3.3. Correlations between miRNAs and Clinical Parameters

Correlation analysis was performed by using the Spearman test. In the ultra-marathon runners’ group, negative correlations were observed between \(\text{VO}_2\text{max}/\text{kg}\) and relative expression of circulating miR-125a-5p and miR-126 \((r = -0.402, p = 0.028; r = -0.438, p = 0.032,\) respectively). Positive correlations were observed between CIMT and circulating miR-125a-5p and miR-126 \((r = 0.388, p = 0.050; r = 0.504, p = 0.023,\) respectively) in ultra-marathon runners.

3.4. Carotid Intima–Media Thickness and miRNAs Expression

ROC analysis showed that miR-126 levels have a good diagnostic performance to predict subjects with increased CIMT. In fact, the area under the curve (AUC) for miR-126 was 0.8 (Figure 2). miR-126 expression levels greater than or equal to the optimal cut-off of 70.6 identified by means of the maximization of the Youden’s function had sensitivity of 83%, specificity of 64%, a negative predictive value of 90%, and a positive predictive value of 50% for the prediction of increased CIMT. Ultra-marathon runners with CIMT > 0.9 mm had 10-fold increased relative expression of miR-126 compared to those with CIMT < 0.9 mm \((p = 0.048)\) (Figure 3).

3.5. Cardiopulmonary Fitness and miRNAs Expression

To analyze the correlation between studied miRNAs expression and \(\text{VO}_2\text{max}/\text{kg}\) in ultra-marathon runners, we divided \(\text{VO}_2\text{max}/\text{kg}\) levels based on quartiles. Ultra-marathon runners with the highest quartile of \(\text{VO}_2\text{max}/\text{kg}\) had 23-fold lower miR-126 expression in comparison to subgroups with lower \(\text{VO}_2\text{max}/\text{kg}\) \((p = 0.017)\). No significant differences were found for miR-125a-5p and Let-7e expressions \((p = 0.059; p = 0.262,\) respectively) (Figure 4).
Figure 2. Receiver operating characteristic (ROC) curves of miR-125a-5p, Let-7e, miR-126 prediction of increased CIMT.

Figure 3. MiRNAs expression difference between CIMT groups in ultra-marathon runners. (a) miR-125a-5p; (b) Let-7e; (c) miR-126, * Comparison is significant at the 0.05 level.
4. Discussion

This study assessed the effects of physical fitness on the levels of miRNAs associated with inflammation, endothelial function, and atherosclerosis in a unique population of high-level long-term ultra-marathon runners. Firstly, our study showed that miR-125a-5p expression was remarkably upregulated in well-trained individuals in comparison to a control group of subjects not engaged in any regular sport activity. In a previous study, even a 2 min all-out running HIIT in young healthy moderately trained individuals was sufficient to increase the expression of circulating miR-125a-5p, which has vasculo-protective functions [47,48]. However, we found a negative correlation between VO$_2$max, which is widely recognized as the best indicator of cardiovascular fitness and aerobic endurance, with both miR-125a-5p and miR-126. Similarly, to our results, the HUNT study also revealed that increased levels of miR-125a were associated with low VO$_2$max in male participants [49]. To the best of our knowledge, miRNAs mentioned above, their association with cardiopulmonary fitness parameters and CIMT have not been extensively studied in individuals who participate in ultra-marathon runs and whose weekly training volume exceeds 70 km of running.

Previously, it was hypothesized that shear stress linked with exercise may stimulate endothelial cells to secrete miRNAs in vivo. Shear stress, particularly when blood flow is disturbed, plays a crucial role in the pathogenesis of the atherosclerotic plaque. Previous in vitro study showed that endothelial cells secrete miR-125a-5p induced by shear stress, which pointed out the vasculoprotective and anti-atherosclerotic potential of miR-125a [48]. Shear stress is essential in controlling the atheroprotective dysfunction of the vessel wall through multifactorial molecular mechanisms that stimulate atherogenesis [50]. Further analysis is needed to confirm the promising value of miRNAs as biomarkers of shear stress in atherosclerosis. HIIT was found to influence the expression of various miRNAs. MiR-125a-5p expression was increased in correlation with HIIT, which may play a role in this phenomenon [48]. However, miR-126 was similarly over-expressed after high-volume training (HVT; 130 min at 55% peak power output-PPO) and sprint-interval training (SIT; 4 × 30 s all-out), but not high-intensity training (HIT; 4 × 4 min at 95% PPO), which may indicate secretion of endothelial miRNAs into the circulation. A study based on
comparison of different exercise protocols speculated that hypoxic conditions are more likely to occur during higher intensities, explaining the largest elevation of circulating miR-126 after SIT [51]. Additionally, it was indicated that endurance exercise causes damage to the endothelial cell layer as confirmed by an increase in circulating miR-126 [22]. It was described that miR-126 is packed into endothelial microparticles under condition of endothelial apoptosis and then transported to target vascular smooth muscle cells in in vitro analysis [51]. This miRNA also diminishes endothelium damage through restoration of autophagic flux by suppressing the PI3K/Akt/mTOR signaling in in vitro model of atherosclerosis [52]. It is important to note that, still there are no specific biomarkers which can identify the best exercise protocol or duration. However, studies showed that an intensity or volume-dependent regulation of angiogenesis, hypoxia and inflammation-related circulating miRNAs, suggesting that the exercise dosage may be a crucial set off.

Further analysis of our results showed that the individuals with the highest quartile of VO$_2$max had a lower expression of miR-125a-5p, miR-126 and Let-7e, where only miR-126 was significantly decreased. Moreover, we found a negative correlation between vasculo-protective miRNAs and VO$_2$max in ultra-marathon runners, namely miR-125a-5p and miR-126. This can be in contradiction to some previous findings that showed a positive correlation between endurance activity, VO$_2$max and the expression of certain miRNAs [11,53]. It is of note that miR-126 levels seem to get easily increased in athletes because of hypoxic stress [51,54]. As hypoxic conditions are more likely to occur during training with higher intensities, it may explain the highest increase of circulating miR-126 after sprint short intensive training [55]. Additionally, various endurance exercises induce the expression of miR-126 and circulating levels of miR-126 have been suggested as a new marker of endothelial injury [56]. It can be speculated that in individuals with higher VO$_2$max lower hypoxic stress after the same intensity of training can be expected, hence lower expression of miR-126. In the functional analysis, with the use of an in vitro model, it was demonstrated that upregulated miR-126 acts as an angiogenesis suppressor under hypoxia conditions [57]. Thus, lower miR-126 expression in our cohort may suggest that lower expression of miR-126 in individuals with higher VO$_2$max serves as an indicator of adaptive processes of enhanced angiogenesis. Of note, highly fit individuals with high VO$_2$max are more likely to develop more severe exercise-induced hypoxemia, due to adaptation to exercise at a greater % of VO$_2$max [58]. Additionally, in vitro studies revealed that miR-126 expression significantly decreased after hypoxia treatment in a time-dependent manner. It was shown that after 6 h in hypoxic conditions miR-126 expression is significantly decreased, reaching even a 100-fold reduction in expression level 24 h after hypoxia treatment. On the other hand the VEGF expression, which is closely associated with neovascularization, has been found to increase 24 h after hypoxia treatment [57]. It should be noted that the VEGF pathway is also related to hypoxia and was described to be differently activated between groups with low and high VO$_2$max. It may play a role in the formation of new capillaries [49,59]. However, it will need to be confirmed in further clinical and experimental studies whether subjects with lower VO$_2$max and elevated miR-126 and miR-125a-5p expression have increased activity in hypoxia- and angiogenesis pathways.

Moreover, we found a significant correlation between VO$_2$max and CIMT ($r = -0.576$, $p = 0.002$). It was previously shown by Kang et al. that high VO$_2$max is related to a decrease in CIMT in comparison to low VO$_2$max, as there was a weak correlation between VO$_2$max and CIMT ($r = -0.129$, $p < 0.001$) [60]. A stronger correlation in our small cohort could be partly explained by higher VO$_2$max values ($60.97 \pm 4.88$ mL/kg/min) in comparison with the subgroup with the highest value from the Kang et al. study ($49.05 \pm 3.47$ mL/kg/min). Interestingly, we also observed a positive association between CIMT and the expression of both miR-125a-5p and miR-126. It was described that miR-126 might serve as a biomarker of atherosclerosis as it exerts anti-apoptotic, anti-inflammatory, regulatory effect on lipid metabolism in endothelial cells. Thus, its over-expression in well trained subjects might be a regulatory mechanism and prevent the atherosclerosis progression and development due
to the suppression of inflammation in atherosclerotic plaque [61]. It was hypothesized that the miR-126 upregulation might play an anti-atherosclerotic role, and may reduce leukocyte migration from the bloodstream through the endothelium to the vessel wall in vivo [62,63]. Interestingly, it was previously described that miR-125a can be downregulated in patients with atherosclerosis [33]. Thus, upregulation may play a protective function, as it has been reported that miR-125a-5p is able to diminish the expression of inflammatory markers in monocytes [64]. Therefore, both miR-125a-5p and miR-126 show the ability to diminish ox-LDL uptake in endothelial cells and monocytes, and thus may protect against the development of atherosclerosis [65]. Those findings were further confirmed in in vitro studies using human brain microvessel endothelial cells, as it was shown that upregulation of miR-125a-5p preserved endothelial cells against ox-LDL-induced cell death, senescence, ROS generation, and NO reduction. Furthermore, increased expression of miR-125a-5p induced the proliferation and migration of endothelial cells, while reducing leukocyte adhesion, and preventing the influence of ox-LDL on these processes [66,67]. Diminished levels of miR-125a-5p were also found to be associated with endothelial dysfunction in children and it may target genes relevant in the context of abnormal endothelial function [68]. Therefore, it can be speculated that miR-125 family might be upregulated during the early inflammation process, which accompany increased intima–media thickness, even though it is downregulated during neointima and plaque formation in atherosclerotic plaques of coronary atherosclerosis patients [33,69]. The above-mentioned observation is especially interesting in light of the previously described long-term effect of endurance exercise training on coronary atherosclerosis. In the athletic cohort coronary artery calcification (CAC) may be present in up to 71% of individuals and coronary artery calcification score CACS > 100 in up to 36%. Moreover, CAC is more common in male marathon runners with additional risk factors like history of hypertension, history of smoking than in athletes without cardiovascular risk factors [10]. What is more important for the marathon runners’ population is that the prevalence of CAC is remarkably higher in the most active athletes in comparison to the least active athletes [10,70].

5. Limitations

One of the major limitations of our study is that we measured miRNAs in a relatively small cohort of 30 ultra-marathon runners. However, according to our best knowledge, this study recruited the largest number of individuals out of any study assessing the expression of circulating miRNAs in athletes. Other limitations are related to the demographic characteristic of individuals regarding gender, and thus our results are not applicable to females. Another limitation is that withdrawing blood between 12–24 h after the last training is a long window as it may affect the expression levels of miRNAs. Moreover, we also measured only selected and known miRNAs using a RT-qPCR, and thus potentially other relevant miRNAs could not be analyzed in this study. As long-term follow-up was not available in this study, no firm conclusions about long-term effects can be drawn from the available data. Moreover, we cannot conclusively state whether the observed changes are harmful or whether any study participant will develop clinically significant atherosclerosis in the future.

6. Conclusions

The study outcomes suggest a possible role of circulating miRNAs as a biomarker of adaptation in the ultra-marathon runner’s cardiovascular system. A positive correlation between miR-125a-5p and miR-126 and CIMT may suggest the possibility that both miRNAs serve as a biomarker for early pathological changes leading to atherosclerosis burden in athletes, however, their predictive value in this setting should be further evaluated. Furthermore, the association between circulating miRNAs and traditional CVD risk factors suggest a potential of these miRNAs as early biomarkers of future cardiovascular health. Future studies will be essential to investigate the impact of extensive and regular physical
exercise on miR-125a-5p and miR-126 uptake or production in the heart and their effect on adaptation of the cardiovascular system to extreme exercise loading.

**Author Contributions:** Conceptualization, C.E. and M.P.; methodology, C.E., M.P. and Ł.A.M.; validation, A.F., D.J. and P.C.; formal analysis, C.E.; investigation, Ł.A.M.; data curation, C.E.; writing—original draft preparation, C.E., A.M., A.C., K.W. and S.D.R.; writing—review and editing, C.E., W.B.; visualization, C.E.; supervision, C.E., M.P. and Ł.A.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** Research subject implemented with CEPT infrastructure financed by the European Union—the European Regional Development Fund within the Operational Program “Innovative economy” for 2007–2013.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Regional Medical Chamber in Warsaw (no 52/17).

**Informed Consent Statement:** Written informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** All datasets used in this study are available to obtain upon request of from the corresponding author.

**Acknowledgments:** This paper was written as a part of cooperation of the international scientific group I-COMET (International Cardiovascular and Cardiometabolic Research Team, www.icomet.science [date of access: 1 July 2021]).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Helgerud, J.; Høydal, K.; Wang, E.; Karlsen, T.; Berg, P.; Bjerkaas, M.; Simonsen, T.; Helgesen, C.; Hjorth, N.; Bach, R.; et al. Aerobic High-Intensity Intervals Improve VO2max More than Moderate Training. *Med. Sci. Sports Exerc.* 2007, 39, 665–671. [CrossRef]

2. Seiler, S.; Tønnessen, E. Intervals, Thresholds and Long Slow Distance: The Role of Intensity and Duration in Endurance Training. *Sportscience* 2009, 13, 32–53.

3. Pelliccia, A.; Caselli, S. Structural and Functional Adaptations in the Athlete’s Heart. In *The ESC Textbook of Sports Cardiology*; Section 1.2.1; Oxford University Press: Oxford, UK, 2019; pp. 9–20. [CrossRef]

4. Machnins, M.J.; Gibala, M.J. Physiological Adaptations to Interval Training and the Role of Exercise Intensity. *J. Physiol.* 2017, 595, 2915–2930. [CrossRef]

5. Malek, Ł.A.; Barczuk-Falecka, M.; Werys, K.; Czajkowska, A.; Mróz, A.; Witek, K.; Burrage, M.; Bakalarski, W.; Nowicki, D.; Roik, D.; et al. Cardiovascular Magnetic Resonance with Parametric Mapping in Long-Term Ultra-Marathon Runners. *Eur. J. Radiol.* 2019, 117, 89–94. [CrossRef]

6. Konwerski, M.; Postuła, M.; Barczuk-Falecka, M.; Czajkowska, A.; Mróz, A.; Witek, K.; Bakalarski, W.; Gąscka, A.; Malek, Ł.A.; Mazurek, T. Epicardial Adipose Tissue and Cardiovascular Risk Assessment in Ultra-Marathon Runners: A Pilot Study. *Int. J. Environ. Res. Public Health* 2021, 18, 3136. [CrossRef] [PubMed]

7. Hellsten, Y.; Nyberg, M. Cardiovascular Adaptations to Exercise Training. *Compr. Physiol.* 2015, 6, 1–32. [CrossRef]

8. Williams, P.T. Physical Fitness and Activity as Separate Heart Disease Risk Factors: A Meta-Analysis. *Med. Sci. Sports Exerc.* 2001, 33, 754–761. [CrossRef] [PubMed]

9. Clanton, T.L. Hypoxia-Induced Reactive Oxygen Species Formation in Skeletal Muscle. *J. Appl. Physiol.* 2007, 102, 2379–2388. [CrossRef]

10. Möhlenkamp, S.; Lehmann, N.; Breuckmann, F.; Bröcker-Preuss, M.; Nassenstein, K.; Halle, M.; Budde, T.; Mann, K.; Barkhausen, J.; Heusch, G.; et al. Running: The Risk of Coronary Events: Prevalence and Prognostic Relevance of Coronary Atherosclerosis in Marathon Runners. *Eur. Heart J.* 2008, 29, 1903–1910. [CrossRef]

11. Soplinska, A.; Zareba, L.; Wicik, Z.; Eyleiten, C.; Jakubik, D.; Siller-Matula, J.M.; De Rosa, S.; Malek, L.A.; Postula, M. MicroRNAs as Biomarkers of Systemic Changes in Response to Endurance Exercise—A Comprehensive Review. *Diagnostics* 2020, 10, 813. [CrossRef]

12. Aengevaeren, V.L.; Mosterd, A.; Braber, T.L.; Prakken, N.H.J.; Doevendans, P.A.; Grobbee, D.E.; Thompson, P.D.; Eijssvogels, T.M.H.; Veltius, B.K. Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. *Circulation* 2017, 136, 138–148. [CrossRef]

13. Merghani, A.; Maestrini, V.; Rosmini, S.; Cox, A.T.; Dhutia, H.; Bastiaenan, R.; David, S.; Yeo, T.J.; Narain, R.; Malhotra, A.; et al. Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes With a Low Atherosclerotic Risk Profile. *Circulation* 2017, 136, 126–137. [CrossRef]
14. Davis, P.H.; Dawson, J.D.; Riley, W.A.; Lauer, R.M. Carotid Intimal-Medial Thickness Is Related to Cardiovascular Risk Factors Measured from Childhood through Middle Age: The Muscatine Study. *Circulation* **2001**, *104*, 2815–2819. [CrossRef] [PubMed]

15. Scuteri, A.; Franco, O.H.; Majiid, A.; Jolita, B.; Sergey, B.; Cheng, H.-M.; Chen, C.-H.; Choi, S.-W.; Francesco, C.; De Buyzere, M.L.; et al. The Relationship between the Metabolic Syndrome and Arterial Wall Thickness: A Mosaic Still to Be Interpreted. *Atherosclerosis* **2016**, *255*, 11–16. [CrossRef] [PubMed]

16. Ebrahim, S.; Papacosta, O.; Whincup, P.; Wannamethee, G.; Walker, M.; Nicolaides, A.N.; Dhananjay, S.; Griffin, M.; Belcaro, G.; Rumley, A.; et al. Carotid Plaque, Intima Media Thickness, Cardiovascular Risk Factors, and Prevalent Cardiovascular Disease in Men and Women: The British Regional Heart Study. *Stroke* **1999**, *30*, 841–850. [CrossRef] [PubMed]

17. Johansen, S.H.; Mathiesen, E.B. Carotid Plaque Compared with Intima-Media Thickness as a Predictor of Coronary and Cerebrovascular Disease. *Curr. Cardiovasc. Res.* **2009**, *11*, 21–27. [CrossRef]

18. Tatsukawa, M.; Sawayama, Y.; Maeda, N.; Okada, K.; Furuysuo, N.; Kashiwagi, S.; Hayashi, J. Carotid Atherosclerosis and Cardiovascular Risk Factors: A Comparison of Residents of a Rural Area of Okinawa with Residents of a Typical Suburban Area of Fukuoka, Japan. *Atherosclerosis* **2004**, *172*, 337–343. [CrossRef]

19. Wójcichowska, A.; Braniecka, A.; Koza-Kamińska, K. MicroRNA in Cardiovascular Biology and Disease. *Adv. Clin. Exp. Med.* **2017**, *26*, 865–874. [CrossRef]

20. Jakubik, D.; Fitas, A.; Eyleiten, C.; Jarosz-Popke, J.; Nowak, A.; Czajka, P.; Wicik, Z.; Sourij, H.; Siller-Matula, J.M.; De Rosa, S.; et al. MicroRNAs and Long Non-Coding RNAs in the Pathophysiological Processes of Diabetic Myopathy: Emerging Biomarkers and Potential Therapeutics. *Cardiovasc. Diabetol.* **2021**, *20*, 55. [CrossRef]

21. Zareba, L.; Fitas, A.; Wolska, M.; Junger, E.; Eyleiten, C.; Wicik, Z.; De Rosa, S.; Siller-Matula, J.M.; Postula, M. MicroRNAs and Long Non-coding RNAs in Coronary Artery Disease: New and Potential Therapeutic Targets. *Cardiol. Clin.* **2020**, *38*, 601–617. [CrossRef]

22. Uhlemann, M.; Möbius-Winkler, S.; Fikenzer, S.; Adam, J.; Redlich, M.; Möhlenkamp, S.; Hilberg, T.; Schuler, G.C.; Adams, V. MicroRNAs as Biomarkers for Acute Atrial Remodeling in Marathon Runners (The miRathon Study—A Sub-Study of the Munich Marathon Study). *PLoS ONE* **2016**, *11*, e0148599. [CrossRef] [PubMed]

23. Nielsen, S.; Åkerström, T.; Rinnov, A.; Yfanti, C.; Scheele, C.; Pedersen, B.K.; Laye, M.J. The miRNA Plasma Signature in Response to Different Forms of Endurance Exercise in Healthy Adults. *Eur. J. Prev. Cardiol.* **2014**, *21*, 484–491. [CrossRef] [PubMed]

24. Clauss, S.; Wakili, R.; Hildebrand, B.; Kääb, S.; Hoster, E.; Klier, I.; Martens, E.; Hanley, A.; Hanssen, H.; Halle, M.; et al. Delivery of microRNA-126 by Apoptotic Bodies Induces CXCL12-Dependent Vascular Protection. *Endothelial-Specific microRNA miR-126 Governs Vascular Integrity and Angiogenesis. J. Physiol.* **2011**, *589*, 3983–3994. [CrossRef]

25. Baggish, A.L.; Hale, A.; Weiner, R.B.; Lewis, G.D.; Systrom, D.; Wang, F.; Wang, T.J.; Chan, S.Y. Dynamic Regulation of Circulating microRNA during Acute Exhaustive Exercise and Sustained Aerobic Exercise Training. *J. Physiol.* **2011**, *589*, 3983–3994. [CrossRef]

26. Pordzik, J.; Pisarz, K.; De Rosa, S.; Jones, A.D.; Eyleiten, C.; Indolfi, C.; Malek, L.; Postula, M. The Potential Role of Platelet-related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review. *Front. Endocrinol.* **2018**, *9*, 74. [CrossRef]

27. Wang, S.; Aurora, A.B.; Johnson, B.A.; Qi, X.; McAnally, J.; Hill, J.A.; Richardson, J.A.; Basel-Duby, R.; Olson, E.N. The Endothelial-Specific microRNA miR-126 Governs Vascular Integrity and Angiogenesis. *Dev. Cell* **2008**, *15*, 261–271. [CrossRef]

28. Zernecke, A.; Bidzhekov, K.; Noels, H.; Shagdarsuren, E.; Gan, L.; Denecke, B.; Hristov, M.; Köppel, T.; Jahantigh, M.N.; Lutgens, E.; et al. MicroRNAs and Long Non-coding RNAs in Coronary Artery Disease: New and Potential Therapeutic Targets. *Cardiol. Clin.* **2020**, *38*, 601–617. [CrossRef]

29. Zareba, L.; Fitas, A.; Wolska, M.; Junger, E.; Eyleiten, C.; Wicik, Z.; De Rosa, S.; Siller-Matula, J.M.; Postula, M. MicroRNAs and Long Non-Coding RNAs in Coronary Artery Disease: New and Potential Therapeutic Targets. *Cardiol. Clin.* **2020**, *38*, 601–617. [CrossRef]

30. Nielseni, S.; Åkerström, T.; Rinnov, A.; Yfanti, C.; Scheele, C.; Pedersen, B.K.; Laye, M.J. Muscle Specific microRNAs Are Regulated by Endurance Exercise in Human Skeletal Muscle. *J. Physiol.* **2010**, *588*, 4029–4037. [CrossRef]
36. Malek, Ł.A.; Mazurkiewicz, Ł.; Marszalek, M.; Barczuk-Falecka, M.; Simon, J.; Grzybowski, J.; Miłosz-Wieczorek, B.; Postula, M.; Marczak, M. Deformation Parameters of the Heart in Endurance Athletes and in Patients with Dilated Cardiomyopathy—A Cardiac Magnetic Resonance Study. Diagnostics 2021, 11, 374. [CrossRef] [PubMed]

37. Kim, J.H.; Malhotra, R.; Chiampas, G.; d’Hemecourt, P.; Troyanos, C.; Cianca, J.; Smith, R.N.; Wang, T.J.; Roberts, W.O.; Thompson, P.D.; et al. Cardiac Arrest during Long-Distance Running Races. N. Engl. J. Med. 2012, 366, 130–140. [CrossRef]

38. Knechtle, B.; Nikolaidis, P.T. Physiology and Pathophysiology in Ultra-Marathon Running. Front. Physiol. 2018, 9, 634. [CrossRef] [PubMed]

39. Gerche, A.L.; La Gerche, A.; Burns, A.T.; Mooney, D.J.; Inder, W.J.; Taylor, A.J.; Bogaert, J.; Maelzaac, A.I.; Heidbüchel, H.; Prior, D.L. Exercise-Induced Right Ventricular Dysfunction and Structural Remodelling in Endurance Athletes. Eur. Heart J. 2012, 33, 998–1006. [CrossRef]

40. Malek, Ł.A.; Czajkowska, A.; Mróz, A.; Witek, K.; Nowicki, D.; Postula, M. Factors Related to Cardiac Troponin T Increase after Participation in a 100 Km Ultra-Marathon. Diagnostics 2021, 10, 167. [CrossRef]

41. Spanidis, Y.; Stagos, D.; Orfanou, M.; Goutzourelas, N.; Bar-Or, D.; Spanididos, D.; Kouretas, D. Variations in Oxidative Stress Levels in 3 Days Follow-up in Ultramarathon Mountain Race Athletes. J. Strength Cond. Res. 2017, 31, 582–594. [CrossRef]

42. Mrakic-Sposta, S.; Gussoni, M.; Moretti, S.; Pratali, L.; Giardini, G.; Tacchini, P.; Dellanoce, C.; Tonacci, A.; Mastorci, F.; Borghini, A.; et al. Effects of Mountain Ultra-Marathon Running on ROS Production and Oxidative Damage by Micro-Invasive Analytic Techniques. PLoS ONE 2015, 10, e0141780. [CrossRef]

43. Gomes, C.P.C.; Oliveira, G.P., Jr.; Madrid, B.; Almeida, J.A.; Franco, O.L.; Pereira, R.W. Circulating miR-1, miR-133a, and miR-206 Levels Are Increased after a Half-Marathon Run. Biomarkers 2014, 19, 585–589. [CrossRef]

44. Harriss, D.J.; MacSweeney, A.; Atkinson, G. Ethical Standards in Sport and Exercise Science Research: 2020 Update. Int. J. Sports Med. 2019, 40, 813–817. [CrossRef]

45. De Rosa, S.; Eposito, F.; Carella, C.; Strangio, A.; Ammirati, G.; Sabatino, J.; Abbate, F.G.; Iaconetti, C.; Liguori, V.; Pergola, V.; et al. Transcoronary Concentration Gradients of Circulating microRNAs in Heart Failure. Eur. J. Heart Fail. 2018, 20, 1000–1010. [CrossRef]

46. De Rosa, R.; De Rosa, S.; Leistner, D.; Boeckel, J.-N.; Keller, T.; Fichtlscherer, S.; Dimmeler, S.; Zeiher, A.M. Transcoronary Concentration Gradient of microRNA-133a and Outcome in Patients With Coronary Artery Disease. Am. J. Cardiol. 2017, 120, 15–24. [CrossRef]

47. Gareri, C.; Iaconetti, C.; Sorrentino, S.; Covello, C.; De Rosa, S.; Indolfi, C. miR-125a-5p Modulates Phenotypic Switch of Vascular Smooth Muscle Cells by Targeting ETS-1. J. Mol. Biol. 2022, 434, 2819–1828. [CrossRef]

48. Schnitz, B.; Breulmann, F.L.; Jubran, B.; Rolfs, F.; Thorwesten, L.; Krüger, M.; Klose, A.; Schnittler, H.-J.; Brand, S.-M. A Three-Step Approach Identifies Novel Shear Stress-Sensitive Endothelial microRNAs Involved in Vasculoprotective Effects of High-Intensity Interval Training (HIIT). Oncotarget 2019, 10, 3625–3640. [CrossRef] [PubMed]

49. Bye, A.; Resjo, H.; Aspens, S.T.; Condorelli, G.; Omland, T.; Wisløff, U. Circulating MicroRNAs and Aerobic Fitness—The HUNT-Study. PLoS ONE 2013, 8, e57496. [CrossRef] [PubMed]

50. Cunningham, K.S.; Gotlieb, A.I. The Role of Shear Stress in the Pathogenesis of Atherosclerosis. Lab. Invest. 2005, 85, 9–23. [CrossRef] [PubMed]

51. Wahl, P.; Wehmeier, U.F.; Jansen, F.J.; Kiliyan, Y.; Bloch, W.; Werner, N.; Mester, J.; Hilberg, T. Acute Effects of Different Exercise Protocols on the Circulating microRNAs -16, -21, and -126 in Trained Subjects. Front. Physiol. 2016, 7, 643. [CrossRef]

52. Tang, F.; Yang, T.-L. MicroRNA-126 Alleviates Endothelial Cells Injury in Atherosclerosis by Restoring Autophagic Flux via Inhibiting of PI3K/Akt/mTOR Pathway. Biochem. Biophys. Res. Commun. 2018, 495, 1482–1489. [CrossRef]

53. Denham, J.; Prestes, P.R. Muscle-Enriched MicroRNAs Isolated from Whole Blood Are Regulated by Exercise and Are Potential Biomarkers of Cardiorespiratory Fitness. Front. Genet. 2016, 7, 196. [CrossRef]

54. Truettner, J.S.; Katsyv, V.; Rosen-Bilgin, N.; Dietrich, W.D.; Dore-Duffy, P. Hypoxia Alters MicroRNA Expression in Rat Cortical Pericytes. Micron 2013, 43, 32–44. [CrossRef] [PubMed]

55. Schmitz, B.; Schelleckes, K.; Nedele, J.; Thorwesten, L.; Klose, A.; Lenders, M.; Brand, E.; Brand, S.-M. Dose-Response of High-Intensity Training (HIT) on Atheroprotective microRNA-126 Levels. Front. Physiol. 2017, 8, 349. [CrossRef] [PubMed]

56. Thum, T. Noncoding RNAs and Myocardial Fibrosis. Nat. Rev. Cardiol. 2014, 11, 655–663. [CrossRef] [PubMed]

57. Ye, P.; Liu, J.; He, F.; Xu, W.; Yao, K. Hypoxia-Induced Deregulation of miR-126 and Its Regulative Effect on VEGF and MMP-9 Expression. Int. J. Med. Sci. 2014, 11, 17–23. [CrossRef] [PubMed]

58. Dempsey, J.A.; Wagner, P.D. Exercise-Induced Arterial Hypoxemia. J. Appl. Physiol. 1999, 87, 1997–2006. [CrossRef]

59. Fasanaro, P.; D’Alessandra, Y.; Di Stefano, V.; Melchionna, R.; Romani, S.; Pomplilio, G.; Capogrossi, M.C.; Martelli, F. MicroRNA-210 Modulates Endothelial Cell Response to Hypoxia and Inhibits the Receptor Tyrosine Kinase Ligand Ephrin-A3. J. Biol. Chem. 2008, 283, 15878–15883. [CrossRef]

60. Kang, S.-J.; Ko, K.-J. Association between Resting Heart Rate, VOmax and Carotid Intima-Media Thickness in Middle-Aged Men. Int. J. Cardiol. Heart Vasc. 2019, 23, 100347. [CrossRef] [PubMed]

61. Hao, X.-Z.; Fan, H.-M. Identification of miRNAs as Atherosclerosis Biomarkers and Functional Role of miR-126 in Atherosclerosis Progression through MAPK Signalling Pathway. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 2725–2733.
62. Van Thienen, J.V.; Fledderus, J.O.; Dekker, R.J.; Rohlena, J.; van Ijzendoorn, G.A.; Kootstra, N.A.; Pannekoek, H.; Horrevoets, A.J.G. Shear Stress Sustains Atheroprotective Endothelial KLF2 Expression More Potently than Statins through mRNA Stabilization. *Cardiovasc. Res.* 2006, 72, 231–240. [CrossRef] [PubMed]

63. Harris, T.A.; Yamakuchi, M.; Ferlito, M.; Mendell, J.T.; Lowenstein, C.J. MicroRNA-126 Regulates Endothelial Expression of Vascular Cell Adhesion Molecule 1. *Proc. Natl. Acad. Sci. USA* 2008, 105, 1516–1521. [CrossRef] [PubMed]

64. Chen, T.; Huang, Z.; Wang, L.; Wang, Y.; Wu, F.; Meng, S.; Wang, C. MicroRNA-125a-5p Partly Regulates the Inflammatory Response, Lipid Uptake, and ORP9 Expression in oxLDL-Stimulated Monocyte/macrophages. *Cardiovasc. Res.* 2009, 83, 131–139. [CrossRef]

65. Wang, J.; Wu, Q.; Yu, J.; Cao, X.; Xu, Z. miR-125a-5p Inhibits the Expression of NLRP3 by Targeting CCL4 in Human Vascular Smooth Muscle Cells Treated with Ox-LDL. *Exp. Ther. Med.* 2019, 18, 1645–1652. [CrossRef]

66. Pan, Q.; Liao, X.; Liu, H.; Wang, Y.; Chen, Y.; Zhao, B.; Lazartigues, E.; Yang, Y.; Ma, X. MicroRNA-125a-5p Alleviates the Deleterious Effects of Ox-LDL on Multiple Functions of Human Brain Microvessel Endothelial Cells. *Am. J. Physiol. Cell Physiol.* 2017, 312, C119–C130. [CrossRef]

67. Pan, Q.; Ma, C.; Wang, Y.; Wang, J.; Zheng, J.; Du, D.; Liao, X.; Chen, Y.; Chen, Y.; Bihl, J.; et al. Microvesicles-Mediated Communication between Endothelial Cells Modulates, Endothelial Survival, and Angiogenic Function via Transferring of miR-125a-5p. *J. Cell. Biochem.* 2019, 120, 3160–3172. [CrossRef]

68. Khalyfa, A.; Kheirandish-Gozal, L.; Bhattacharjee, R.; Khalyfa, A.A.; Gozal, D. Circulating microRNAs as Potential Biomarkers of Endothelial Dysfunction in Obese Children. *Chest* 2016, 149, 786–800. [CrossRef]

69. De Gonzalo-Calvo, D.; Dávalos, A.; Fernández-Sanjurjo, M.; Amado-Rodríguez, L.; Díaz-Coto, S.; Tomás-Zapico, C.; Montero, A.; García-González, A.; Llorente-Cortés, V.; Heras, M.E.; et al. Circulating microRNAs as Emerging Cardiac Biomarkers Responsive to Acute Exercise. *Int. J. Cardiol.* 2018, 264, 130–136. [CrossRef]

70. DeFina, L.F.; Radford, N.B.; Barlow, C.E.; Willis, B.L.; Leonard, D.; Haskell, W.L.; Farrell, S.W.; Pavlovic, A.; Abel, K.; Berry, J.D.; et al. Association of All-Cause and Cardiovascular Mortality With High Levels of Physical Activity and Concurrent Coronary Artery Calcification. *JAMA Cardiol.* 2019, 4, 174–181. [CrossRef] [PubMed]